DeVries A, Munzenrider J E, Hedley-Whyte T, Hug E B
Klinik für Strahlentherapie und Radioonkologie, Leopold-Franzens Universität, Innsbruck, Osterreich.
Strahlenther Onkol. 1999 Feb;175(2):62-7. doi: 10.1007/BF02753844.
Most malignant meningiomas will recur following surgical resection only. The role of irradiation and radiation dose levels is poorly defined. This study reviews a single institution experience using both, conventional and high doses > or = 60 Gy/CGE radiation regimen.
Between 1974 and 1995 16 patients with histologically proven malignant meningioma underwent radiation therapy (RT). Age at diagnosis ranged between 6 and 79 years (median: 49 years). Three patients reported previous irradiation to the head at least 14 years prior to diagnosis. Ten patients were treated for primary, and 6 patients for recurrent disease. Six patients underwent gross total and 10 patients subtotal resection (Table 1). RT was delivered using conventional, megavoltage photons or combined 160 MeV proton and photon irradiation. Except 1 patient, who died during RT, the radiation doses ranged between 40 and 70 Gy/CGE (= Cobalt Gray Equivalent) (median: 58 Gy/CGE, Table 2).
With median observation time of 59 months (range: 10 to 155 months), actuarial local control rates at 5 and 8 years were 52% and 17%, respectively. Target doses > or = Gy/CGE resulted in significantly improved tumor control (100%) compared to < 60 Gy/CGE (17%) (p = 0.0006, Table 3 and Figure 1). Improved local control translated also in increased overall survival: 87% (> or = 60 Gy/CGE) versus 15% (< 60 Gy/CGE) at 5 years (p = 0.025, Figure 2). At time of analysis, 6/16 patients (38%) were alive. Two patients developed symptomatic brain damage at doses of 59.3 and 72 Gy/CGE.
Conformal, radiation therapy with target doses > or = 60 Gy/CGE, in this study by use of combined proton and photon irradiation, can significantly improve chances of long-term local control and survival for patients diagnosed with these challenging tumors.
大多数恶性脑膜瘤仅通过手术切除后会复发。放疗及放疗剂量水平的作用尚不明确。本研究回顾了一家机构使用传统放疗和剂量≥60 Gy/CGE的高剂量放疗方案的经验。
1974年至1995年间,16例经组织学证实的恶性脑膜瘤患者接受了放射治疗(RT)。诊断时年龄在6岁至79岁之间(中位数:49岁)。3例患者报告在诊断前至少14年曾接受过头颅放疗。10例患者接受原发性疾病治疗,6例患者接受复发性疾病治疗。6例患者接受了全切除,10例患者接受了次全切除(表1)。使用传统的兆伏光子或160 MeV质子与光子联合照射进行放疗。除1例患者在放疗期间死亡外,放疗剂量在40至70 Gy/CGE(=钴灰当量)之间(中位数:58 Gy/CGE,表2)。
中位观察时间为59个月(范围:10至155个月),5年和8年的精算局部控制率分别为52%和17%。与<60 Gy/CGE(17%)相比,目标剂量≥60 Gy/CGE可显著提高肿瘤控制率(100%)(p = 0.0006,表3和图1)。局部控制的改善也转化为总生存率的提高:5年时为87%(≥60 Gy/CGE)对15%(<60 Gy/CGE)(p = 0.025,图2)。在分析时,16例患者中有6例(38%)存活。2例患者在剂量为59.3和72 Gy/CGE时出现了有症状的脑损伤。
在本研究中,通过使用质子与光子联合照射,目标剂量≥60 Gy/CGE的适形放疗可显著提高被诊断患有这些具有挑战性肿瘤患者的长期局部控制和生存几率。